Nordic Capital-backed LEO Pharma to acquire dersimelagon rights from Bain-owned Tanabe for $435m
Monday, October 26, 2026 · first reported by PEI Private Equity
Nordic Capital-backed LEO Pharma will acquire dersimelagon rights from Bain-owned Tanabe for $435 million.
- Firm
- Nordic Capital
- Also named
- LEO Pharma, Bain Capital, Tanabe
- Deal value
- $435M
- Asset class
- Private equity
- Geography
- Europe
The summary and fields above are extracted from the published reports and can contain errors. The linked articles are the source of record.
Coverage
1 source- Bain Capital to retain 40% stake in $6bn Surgery Partners take-privatePrivate Equity Wire +1
- Veritas Capital Is Exploring a Sale of Aerospace Aftermarket Company Chromalloy That Could Fetch More Than $10 BillionHedgeCo
- Mubadala, Brookfield reportedly back AVID’s $1.54b bid for Ingenia CommunitiesIREI +1
- IDG Capital leads bidding for ASMPT unit valued above $1bnPrivate Equity Wire
- Meiji Yasuda to acquire 5% stake in Man Group in $239m dealPrivate Equity Wire
- OUE REIT pays A$864m for additional 50% stake in Sydney’s Salesforce TowerIPE Real Assets